Silence Therapeutics plc (SLN) Cash Flow Statement
Silence Therapeutics plc (SLN) generated -$42.3M of operating cash flow over the twelve months to 2026-06-30, spent $3000 on capital expenditure and had free cash flow of -$42.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SLNSilence Therapeutics plcFollow SLN — free
—
Price chart with a free account
- Market cap
- 929.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | — | -67.6 | -62.3 | -42.3 | |
| Capital expenditure | — | 0.2 | 0.1 | -0.0 | |
| Free cash flow | — | -67.9 | -62.3 | -42.3 | |
| Stock-based compensation | — | 16.3 | 8.1 | — |
USD millions · SEC XBRL
Silence Therapeutics plc — questions
- What is Silence Therapeutics plc's operating cash flow?
- -$42.3M over the twelve months to 2026-06-30.
- How much does Silence Therapeutics plc spend on capital expenditure?
- $3000 over the twelve months to 2026-06-30.
- What is Silence Therapeutics plc's free cash flow?
- -$42.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Silence Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.